Last reviewed · How we verify

Clindamycin and BPO 5% gel

Stiefel, a GSK Company · FDA-approved active Small molecule

Clindamycin and BPO 5% gel is a Topical antibiotic combination with keratolytic agent Small molecule drug developed by Stiefel, a GSK Company. It is currently FDA-approved for Acne vulgaris. Also known as: Duac Topical Gel.

Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production.

Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production. Used for Acne vulgaris.

At a glance

Generic nameClindamycin and BPO 5% gel
Also known asDuac Topical Gel
SponsorStiefel, a GSK Company
Drug classTopical antibiotic combination with keratolytic agent
TargetBacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO)
ModalitySmall molecule
Therapeutic areaDermatology
PhaseFDA-approved

Mechanism of action

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, effectively killing Propionibacterium acnes. Benzoyl peroxide (BPO) is an oxidizing agent that generates reactive oxygen species to destroy bacterial cell walls and also helps reduce comedone formation by normalizing follicular keratinization. The combination provides synergistic antibacterial activity and reduces the risk of antibiotic resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clindamycin and BPO 5% gel

What is Clindamycin and BPO 5% gel?

Clindamycin and BPO 5% gel is a Topical antibiotic combination with keratolytic agent drug developed by Stiefel, a GSK Company, indicated for Acne vulgaris.

How does Clindamycin and BPO 5% gel work?

Clindamycin kills acne-causing bacteria while benzoyl peroxide oxidizes and destroys bacterial cell membranes and reduces sebum production.

What is Clindamycin and BPO 5% gel used for?

Clindamycin and BPO 5% gel is indicated for Acne vulgaris.

Who makes Clindamycin and BPO 5% gel?

Clindamycin and BPO 5% gel is developed and marketed by Stiefel, a GSK Company (see full Stiefel, a GSK Company pipeline at /company/stiefel-a-gsk-company).

Is Clindamycin and BPO 5% gel also known as anything else?

Clindamycin and BPO 5% gel is also known as Duac Topical Gel.

What drug class is Clindamycin and BPO 5% gel in?

Clindamycin and BPO 5% gel belongs to the Topical antibiotic combination with keratolytic agent class. See all Topical antibiotic combination with keratolytic agent drugs at /class/topical-antibiotic-combination-with-keratolytic-agent.

What development phase is Clindamycin and BPO 5% gel in?

Clindamycin and BPO 5% gel is FDA-approved (marketed).

What are the side effects of Clindamycin and BPO 5% gel?

Common side effects of Clindamycin and BPO 5% gel include Skin irritation, Dryness, Erythema, Peeling, Contact dermatitis.

What does Clindamycin and BPO 5% gel target?

Clindamycin and BPO 5% gel targets Bacterial 50S ribosome (clindamycin); oxidative damage to bacterial cell membranes (BPO) and is a Topical antibiotic combination with keratolytic agent.

Related